Skip to main navigation menu Skip to main content Skip to site footer
Español (España) | English
Editorial
Revistas/Journals
Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home
Issue
Current Issue Archives Special Issue
About
About the Journal Editorial Team Privacy Statement Digital preservation policy Contact
Author Guidelines
Guidelines for authors Peer Review Process Open Access Policy and Copyright Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
×
Español (España) | English
Editorial

Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home

Current Issue Archives Special Issue

About the Journal Editorial Team Privacy Statement Digital preservation policy Contact

Guidelines for authors Peer Review Process Open Access Policy and Copyright Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
Systematic reviews or meta-analyses
Published: 2023-10-15
DOI: https://doi.org/10.56294/saludcyt2023563

Cardiometabolic effect of sodium and glucosa cotransporter inhibitors type 2

By
Melissa Olmedo-Muñoz ,
Melissa Olmedo-Muñoz

Universidad Técnica Ambato, Ambato, Ecuador

Search this author on:

PubMed | Google Scholar
Ricardo Recalde-Navarrete ,
Ricardo Recalde-Navarrete

Universidad Técnica Ambato, Ambato, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Type 2 diabetes mellitus has emerged as a leading cause of premature death and a growing threat to the healthcare system due to the high costs of medical care in the context of cardiovascular complications.
Methods: We conducted a systematic electronic search of clinical trials published from 2015 to January 2023 in PubMed, Scopus, Web of Science and ScieLO databases, which evaluated the efficacy and safety of the use of type 2 sodium-glucose cotransporter inhibitors in patients with type 2 diabetes mellitus and established cardiovascular disease on routine treatment and their cost-effectiveness.
Results: Significantly lower rates of acute myocardial infarction, stroke, cardiovascular death and hospitalization due to heart failure were observed when the study drugs were added to standard therapy. In addition, it was evidenced that the reduction in cardiovascular clinical events manages to offset the cost of type 2 sodium-glucose cotransporter inhibitors resulting in a cost-effective use of resources at the health care level.
Conclusions: As the transition to a new evidence-based era of managing patients with type 2 diabetes mellitus and cardiovascular disease progresses, it is imperative that new therapies are developed that not only improve glycemic control, but also improve cardiovascular outcomes, because these events represent the major cause of mortality in this population.

Keywords:

diabetes,
cotransporter,
sodium,
glucose,
cardioprotection,
cost effectiveness,

How to Cite

1.
Olmedo-Muñoz M, Recalde-Navarrete R. Cardiometabolic effect of sodium and glucosa cotransporter inhibitors type 2. Salud, Ciencia y Tecnología [Internet]. 2023 Oct. 15 [cited 2024 Jul. 27];3:563. Available from: https://revista.saludcyt.ar/ojs/index.php/sct/article/view/563

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

Vol. 3 (2023)
See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.